Canaccord Genuity Group Increases Ventyx Biosciences (NASDAQ:VTYX) Price Target to $54.00
Canaccord Genuity Group Increases Ventyx Biosciences (NASDAQ:VTYX) Price Target to $54.00
Ventyx Biosciences (NASDAQ:VTYX – Get Rating) had its target price boosted by Canaccord Genuity Group from $35.00 to $54.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the stock. Canaccord Genuity Group's price target suggests a potential upside of 32.19% from the stock's previous close.
據Benzinga報道,在週二發佈的一份報告中,Cancord Genuity Group將文蒂克斯生物科學公司(納斯達克:VTYX-GET評級)的目標價從35美元上調至54美元。該公司目前對該股的評級為“買入”。Canaccel Genuity Group的目標價表明,該股較前一交易日收盤價有32.19%的潛在上漲空間。
Other equities research analysts also recently issued reports about the company. Oppenheimer lifted their price objective on Ventyx Biosciences from $55.00 to $60.00 and gave the stock an "outperform" rating in a report on Friday, January 27th. The Goldman Sachs Group initiated coverage on Ventyx Biosciences in a report on Monday, December 19th. They set a "buy" rating and a $50.00 price objective on the stock. Evercore ISI lifted their price objective on Ventyx Biosciences from $50.00 to $65.00 in a report on Thursday, January 26th. Finally, Morgan Stanley initiated coverage on Ventyx Biosciences in a report on Thursday, November 17th. They set an "overweight" rating and a $45.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $52.78.
其他股票研究分析師最近也發佈了關於該公司的報告。奧本海默在1月27日(星期五)的一份報告中將Ventyx Biosciences的目標價從55.00美元上調至60.00美元,並給予該股“跑贏大盤”的評級。高盛在12月19日星期一的一份報告中發起了對文蒂克斯生物科學的報道。他們為該股設定了“買入”評級和50美元的目標價。Evercore ISI在1月26日星期四的一份報告中將Ventyx Biosciences的目標價從50.00美元上調至65.00美元。最後,摩根士丹利在11月17日星期四的一份報告中發起了對文迪思生物科學的報道。他們為該股設定了“增持”評級和45.00美元的目標價。根據MarketBeat.com的數據,八位股票研究分析師對該股的評級為買入,該公司的普遍評級為買入,平均目標價為52.78美元。
Ventyx Biosciences Trading Down 2.7 %
Ventyx生物科學公司股價下跌2.7%
Shares of NASDAQ:VTYX opened at $40.85 on Tuesday. Ventyx Biosciences has a one year low of $9.50 and a one year high of $44.12. The business's 50-day simple moving average is $32.44 and its 200 day simple moving average is $28.16.
納斯達克:VTYX的股價週二開盤報40.85美元。Ventyx Biosciences的一年低點為9.50美元,一年高位為44.12美元。該業務的50日簡單移動均線切入位為32.44美元,200日簡單移動均線切入位為28.16美元。
Insider Transactions at Ventyx Biosciences
文蒂克斯生物科學公司的內幕交易
In other news, insider John Nuss sold 50,000 shares of Ventyx Biosciences stock in a transaction that occurred on Monday, December 5th. The stock was sold at an average price of $28.23, for a total value of $1,411,500.00. Following the completion of the transaction, the insider now owns 258,696 shares in the company, valued at approximately $7,302,988.08. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider John Nuss sold 50,000 shares of the company's stock in a transaction on Monday, December 5th. The stock was sold at an average price of $28.23, for a total transaction of $1,411,500.00. Following the completion of the transaction, the insider now directly owns 258,696 shares in the company, valued at approximately $7,302,988.08. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Somu Subramaniam sold 3,935 shares of the company's stock in a transaction on Monday, November 7th. The stock was sold at an average price of $29.08, for a total value of $114,429.80. Following the transaction, the director now owns 16,888,593 shares of the company's stock, valued at $491,120,284.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,206,646 shares of company stock worth $36,781,043. 49.10% of the stock is currently owned by corporate insiders.
在其他新聞方面,內部人士約翰·努斯在12月5日星期一的一筆交易中出售了50,000股Ventyx Biosciences股票。股票以28.23美元的平均價格出售,總價值為1,411,500.00美元。交易完成後,這位內部人士現在擁有該公司258,696股,價值約7,302,988.08美元。這筆交易是在提交給美國證券交易委員會的法律文件中披露的,該文件可通過此超鏈接。在相關新聞中,內部人士約翰·努斯在12月5日星期一的一筆交易中出售了5萬股該公司股票。該股以28.23美元的平均價格出售,總成交金額為1,411,500.00美元。交易完成後,這位內部人士現在直接擁有該公司258,696股,價值約7,302,988.08美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過這個環節。此外,在11月7日星期一的一筆交易中,董事Somu Subramaniam出售了3935股該公司股票。這隻股票的平均售價為29.08美元,總價值為114,429.80美元。交易完成後,董事現在擁有該公司16,888,593股股票,價值491,120,284.44美元。關於這次銷售的披露可以找到這裏。在上個季度,內部人士出售了1206646股公司股票,價值36,781,043美元。49.10%的股份目前由企業內部人士持有。
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors have recently added to or reduced their stakes in the stock. Birchview Capital LP grew its stake in Ventyx Biosciences by 36.4% during the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the company's stock worth $1,571,000 after buying an additional 12,000 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of Ventyx Biosciences in the third quarter worth $4,072,000. TD Asset Management Inc. bought a new position in shares of Ventyx Biosciences in the third quarter worth $570,000. The Manufacturers Life Insurance Company bought a new position in shares of Ventyx Biosciences in the third quarter worth $980,000. Finally, SG Americas Securities LLC bought a new position in shares of Ventyx Biosciences in the third quarter worth $132,000. 95.57% of the stock is currently owned by institutional investors.
機構投資者最近增持或減持了該股。第三季度,Birchview Capital LP在Ventyx Biosciences的持股增加了36.4%。Birchview Capital LP現在擁有45,000股該公司股票,價值1,571,000美元,上個季度又購買了12,000股。Nantahala Capital Management LLC在第三季度購買了價值4,072,000美元的Ventyx Biosciences的新頭寸。TD Asset Management Inc.在第三季度購買了價值57萬美元的Ventyx Biosciences股票的新頭寸。製造商人壽保險公司在第三季度購買了價值98萬美元的文蒂克斯生物科學公司的新股票頭寸。最後,SG America Securities LLC在第三季度購買了價值13.2萬美元的Ventyx Biosciences股票的新頭寸。95.57%的股票目前由機構投資者持有。
About Ventyx Biosciences
關於Ventyx生物科學公司
(Get Rating)
(獲取評級)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
文蒂克斯生物科學公司是一家臨牀階段的生物製藥公司,開發用於治療一系列炎症性疾病的小分子候選產品。它的主要臨牀候選產品是VTX958,這是一種治療牛皮癬、牛皮癬關節炎和克羅恩病的選擇性變構酪氨酸激酶2型抑制劑。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Ventyx Biosciences (VTYX)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
- 免費獲取StockNews.com關於Ventyx生物科學的研究報告(VTYX)
- Bed Bath&Beyond正在繞着排水溝走
- Allegro MicroSystems是一隻定位良好的半導體股票
- 斯科特奇蹟-Gro觸底,比賽逆轉
- 奧馳亞是一隻大衰退的股票,長期前景不確定
- Novavax的股價在1月份大幅上漲,而其他股票則出現下滑
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Ventyx生物科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ventyx Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。